Abbott and Eisai to launch Humira, rheumatoid arthritis therapy.

Abbott Korea and Eisai Korea jointly launched a new type of rheumatoid arthritis drug called "Humira", having mode of selectively suppressing the TNF-alfa that linked with the occurrence and progress of the rheumatoid arthritis.

Unlike conventional RA therapy it is an antibody made by 100% of human gene recombinant anti-TNF cloning, which is similar to molecular naturally found in our body,...